Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Taipei Exchange - Delayed Quote TWD

Daiken Biomedical Co., Ltd. (7780.TWO)

152.50
+1.00
+(0.66%)
At close: April 30 at 2:54:19 PM GMT+8
Loading Chart for 7780.TWO
  • Previous Close 151.50
  • Open 151.50
  • Bid 152.00 x --
  • Ask 153.50 x --
  • Day's Range 151.50 - 152.50
  • 52 Week Range 81.00 - 192.00
  • Volume 9,324
  • Avg. Volume 9,498
  • Market Cap (intraday) 9.15B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 63.02
  • EPS (TTM) 2.42
  • Earnings Date --
  • Forward Dividend & Yield 2.86 (1.88%)
  • Ex-Dividend Date Feb 26, 2025
  • 1y Target Est --

Daiken Biomedical Co., Ltd. engages in the research and development of healthy food products. The company is based in Taipei, Taiwan. Daiken Biomedical Co., Ltd. is a subsidiary of Sunfun Info Co., Ltd.

certifications.nutrasource.ca/certified-products/brand?id=DABI

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 7780.TWO

View More

Performance Overview: 7780.TWO

Trailing total returns as of 4/30/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

7780.TWO
15.40%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
12.16%

1-Year Return

7780.TWO
88.27%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
0.79%

3-Year Return

7780.TWO
88.27%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
21.96%

5-Year Return

7780.TWO
88.27%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
84.09%

Compare To: 7780.TWO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 7780.TWO

View More

Valuation Measures

Annual
As of 4/30/2025
  • Market Cap

    9.15B

  • Enterprise Value

    8.02B

  • Trailing P/E

    62.76

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    4.91

  • Price/Book (mrq)

    7.00

  • Enterprise Value/Revenue

    5.88

  • Enterprise Value/EBITDA

    53.50

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    7.82%

  • Return on Assets (ttm)

    8.15%

  • Return on Equity (ttm)

    13.71%

  • Revenue (ttm)

    1.36B

  • Net Income Avi to Common (ttm)

    106.58M

  • Diluted EPS (ttm)

    2.42

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.14B

  • Total Debt/Equity (mrq)

    0.17%

  • Levered Free Cash Flow (ttm)

    171.51M

Research Analysis: 7780.TWO

View More

Company Insights: 7780.TWO

Research Reports: 7780.TWO

View More